Sort
30,917 grants matching “tumor microenvironment”
Selenium in gastrointestinal inflammatory diseases
$343,650Christopher S. Williams · Vanderbilt University Medical Center · R01 · FY2018 · DK
Selenium in gastrointestinal inflammatory diseases
$343,650Christopher S. Williams · Vanderbilt University Medical Center · R01 · FY2016 · DK
MYELOID-DERIVED SUPPRESSOR CELL EFFECTS ON ANTIBODY THERAPY
$343,613William E. Carson · Ohio State University · P01 · FY2014 · CA
Heparanase in Tumor Progression, Metastasis and Chemoresistance
$343,602Ralph D Sanderson · University Of Alabama At Birmingham · R01 · FY2019 · CA
Induction of Therapeutic Immunity in the Tumor Microenvironment
$343,580Walter J Storkus · University Of Pittsburgh At Pittsburgh · R01 · FY2017 · CA
Targeting the HIF-2 Signaling Pathway as a Radioprotective Strategy for Bone
$343,574Colleen Wu · Duke University · R01 · FY2024 · AR
Targeting cell trafficking as a new therapeutic modality for Multiple Myeloma
$343,498Irene M. Ghobrial · Dana-Farber Cancer Inst · R01 · FY2011 · CA
Dysregulation of Antigen Presenting Cell Function in Cancer
$343,485Paul Roche · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Dual-pronged nano-drug delivery using plant virus-like particles
$343,474Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2025 · CA
The role of HIF2alpha in colon carcinogenesis
$343,473Yatrik M Shah · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
$343,436David E Fisher · Massachusetts General Hospital · P01 · FY2020 · CA
MyD88-bearing tumors in immune-regulation and chemo-resistance
$343,413Gil G Mor · Yale University · R01 · FY2009 · CA
MOSAIC: Targeting the Tissue State
$343,413Nhan L Tran · Mayo Clinic Arizona · U54 · FY2023 · CA
MyD88-bearing tumors in immune-regulation and chemo-resistance
$343,413Gil G Mor · Yale University · R01 · FY2010 · CA
MyD88-bearing tumors in immune-regulation and chemo-resistance
$343,413Gil G Mor · Yale University · R01 · FY2008 · CA
Targeting Endoplasmic Reticulum Stress Sensor IRE1 to Enhance Chemotherapy Sensitivity in MYC-driven breast cancer
$343,397Xi Chen · Baylor College Of Medicine · P50 · FY2020 · CA
Exploiting Cancer Metabolism and Drug Efflux with Bystander-Assisted Immunotherapy
$343,396Rock Mancini · Washington State University · R01 · FY2021 · CA
Targeting immune stroma interactions in pancreatic cancer
$343,355Gregory B. Lesinski · Emory University · R01 · FY2019 · CA
Core transcriptional regulators of malignant stem cell generation in multiple myeloma
$343,355Leslie A Crews · University Of California, San Diego · R37 · FY2024 · CA
Elucidation and therapeutic exploitation of PAK mediated radioresistance
$343,355Sunil J Advani · University Of California, San Diego · R37 · FY2024 · CA
Characterization of WWOX, the Cancer Gene Spanning FRA16D
$343,332Claudio Marcelo Aldaz · University Of Tx Md Anderson Can Ctr · R01 · FY2010 · CA
RP-3: Elucidating Mechanisms of Sensitivity and Resistance to Checkpoint Blockade Therapy for Rational Multi-Drug Immunotherapy in Urothelial Cancers
$343,314Timothy An-Thy Chan · Sloan-Kettering Inst Can Research · P50 · FY2019 · CA
RP-3: Elucidating Mechanisms of Sensitivity and Resistance to Checkpoint Blockade Therapy for Rational Multi-Drug Immunotherapy in Urothelial Cancers
$343,314Jonathan Eric Rosenberg · Sloan-Kettering Inst Can Research · P50 · FY2022 · CA
Resistance to Cancer Therapeutics Through Microenvironment Damage Responses.
$343,288Peter S Nelson · Fred Hutchinson Cancer Research Center · R01 · FY2013 · CA
Site Specific Drug Delivery with Light-responsive Conjugates for Photo-biomodulation
$343,252Youngjae You · State University Of New York At Buffalo · R01 · FY2025 · GM